查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1425077

生物银行市场 – 2024 年至 2029 年预测

Biobanking Market - Forecasts from 2024 to 2029
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 140 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

2022年生物银行市值为607.35亿美元，复合年增长率为5.68%，到2029年市场规模将达到894.11亿美元。

生物银行的过程涉及收集和储存可用于研究、生物多样性研究和诊断的生物样本。生物样本库对于支持生物医学研究、提供个人化治疗以及保持最新的年龄人口统计记录至关重要。

生物银行市场驱动因素

该行业受到对尖端治疗方法研究和开发的大量投资的推动，包括个人化医疗、再生医学和癌症基因组学研究。此外，大流行的出现使生物样本库处于大流行对策的最前沿，推动了生物样本库市场的有机收益成长。生物银行对于诊断各种疾病和开发治疗药物至关重要。国际社会迫切需要努力生产疫苗和其他药物来阻止病毒的传播。

慢性病流行

近年来，由于患者生活方式和饮食习惯的改变，慢性病迅速增加。例如，根据世界卫生组织（WHO）的报告，心血管疾病是全球第一大死因。除此之外，人口老化的加剧以及肥胖和糖尿病患者数量的增加是生物样本库产业的主要驱动力。心血管和神经系统疾病盛行率的增加预计也将推动生物样本库市场的发展。这些疾病导致的死亡风险增加也增加了医疗诊断的使用。

政府倡议不断增多

生物样本库样本申请的增加、商业和公共机构对生物银行的融资增加、生物银行是全球生物样本库市场增长的主要驱动力。例如，2021 年 1 月，联邦教育和研究部承诺在三年内提供 350 万欧元贷款，以支持德国生物银行节点活动。此外，维多利亚州政府于 2021 年 5 月向 Doherty 研究所的 COVID-19 生物库提供了 500 万美元。

基因组研究活动的增加

推动全球生物样本库市场扩张的主要原因之一是疾病研究基因组研究倡议的增加。为了各种健康益处而保存婴儿脐带血干细胞的日益增长的趋势以及再生医学研究的公共和私人资金筹措正在推动生物样本库市场的成长。此外，世界范围内严重疾病的日益流行以及对具有成本效益的药物开发的需求也正在影响市场。此外，生物银行市场也受到生物技术产业的成长、医疗保健产业的进步、人口成长、医疗保健支出增加以及生物银行的突破性进展的有利影响。

血液製品生物银行

预计在预测期内血液製品将会增加。这是由于意外和血液疾病的增加。血液和血液製品是最常被采集的检体，也是 DNA 和 RNA 的一级资讯来源，目前占据了生物样本库市场的大部分。血液相关产品的需求以及血液相关疾病盛行率的上升正在推动血液产品的扩张。此外，老年人口的增加是推动血液製品生物样本库市场成长的主要因素。

虚拟生物库受欢迎

从传统生物库中储存的样本中收集和表征的资料将在虚拟储存库中提供。虚拟生物库资料库提供样本的高解析度照片和其他识别资讯。虚拟生物库经常用于生物资讯学，包含有价值的临床切片检查样本的 2D 和 3D 显微镜记录。这种方法已成为提高样本可见性和可访问性的可行选择。虚拟生物样本库使研究人员能够找到管理和简化生物银行流程中关键步骤所需的产品和服务。生物样本库市场的未来成长可能来自虚拟系统整合。

再生医学的采用增加

再生疗法诱导细胞、组织和器官的再生并支持功能恢復。每年，都会向食品药物管理局(FDA) 提交多项再生医学人体临床试验请求。全球生物样本库市场的快速扩张可能归因于再生医学行业开发慢性疾病有效治疗方法的能力。生物样本库为研究、开发和治疗提供样本，使其成为再生疗法开发的宝贵资源。投资生物银行可以显着回收成本，以支持组织工程和再生医学计画。

预计欧洲将占据生物银行市场的最大份额

预计欧洲将占据生物样本库产业的最大份额。丹麦、挪威和瑞典等欧洲国家都已建立生物样本库，为生物样本库市场的成长做出了重大贡献。因此，由于欧洲样本供应的增加，生物银行领域不断扩大。近年来，生物样本库市场的扩张是由製药公司研发支出的增加以及欧洲虚拟生物银行技术的日益使用所推动的。

目录

第一章简介

  • 市场概况
  • 市场定义
  • 调查范围
  • 市场区隔
  • 货币
  • 先决条件
  • 基准年和预测年时间表

第二章调查方法

  • 调查资料
  • 先决条件

第三章执行摘要

  • 研究亮点

第四章市场动态

  • 市场驱动因素
  • 市场限制因素
  • 波特五力分析
  • 产业价值链分析

第五章生物银行市场：依样本类型

  • 介绍
  • 血液製品
  • 人体组织
  • 细胞株
  • 核酸
  • 体液
  • 人类排泄物

第六章生物银行市场：依所有权分类

  • 介绍
  • 大学
  • 国家/地方机构
  • 非营利机构
  • 私人组织

第七章生物银行市场：依应用分类

  • 介绍
  • 再生医学
  • 生命科学研究
  • 临床调查

第八章生物银行市场：依最终用途分类

  • 介绍
  • 製药公司
  • 学术研究所
  • 医院

第九章生物银行市场：按地区

  • 介绍
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他的
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 西班牙
    • 其他的
  • 中东/非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 以色列
    • 其他的
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 韩国
    • 印尼
    • 泰国
    • 其他的

第十章竞争环境及分析

  • 主要企业及策略分析
  • 市场占有率分析
  • 合併、收购、协议和合作

第十一章 公司简介

  • Sapien Biosciences
  • Hamilton Company
  • UK Biobank
  • Apollo Hospitals
  • Banka Bio
  • Labvantage
  • Amgen
  • BioKryo
  • Thermo Fisher Scientific
  • Cureline
简介目录
Product Code: KSI061616596

The biobanking market is evaluated at US$60.735 billion for the year 2022 growing at a CAGR of 5.68% reaching the market size of US$89.411 billion by the year 2029.

The process of biobanking involves gathering and preserving biological samples that can later be utilised for research, studies of biodiversity, and diagnostics. To support biomedical research investigations, provide personalised treatment, and keep age demographic records current, biobanks are essential.

Driving factors for the biobanking market

The field is being driven by significant investments in the research and development of cutting-edge therapeutics including personalised medicine, regenerative medicine, and cancer genomic investigations. Additionally, the emergence of the pandemic has positioned biobanks at the forefront of pandemic control efforts, propelling the bio-banking market's organic revenue growth. For the diagnosis and creation of medications for a range of illnesses, biobanking is crucial. There has been an urgent need for international initiatives to generate vaccinations and other medications to stop the spread of the virus.

Growing prevalence of chronic diseases

Chronic diseases have grown exponentially in recent years owing to the changing lifestyle and eating habits of patients. For instance, according to the World Health Organization report, cardiovascular disease is considered the leading cause of death globally. In addition to this, the rising geriatric population and, the increase in the number of people suffering from obesity, and diabetes are the key drivers for the bio-banking industry. An increase in the prevalence of cardiovascular and neurological disorders is also anticipated to fuel the bio-banking market. The rise in mortality risk with such disorders is also increasing the utilization of medical diagnosis.

Rising government initiatives

Increased applications for biobanked samples, increased financing for biobanking from commercial & public organisations, increased genomic research efforts, and increased investment in R&D activities by various healthcare firms are the main drivers of bio-banking market growth for biobanking globally. For instance, in January 2021, the Federal Ministry of Education and Research committed €3.5 million in financing for three years to support the German Biobank Node activity. Additionally, the Victorian government gave the COVID-19 biobank at the Doherty Institute $5 million in May 2021.

Increase in genomic research activities

One of the key reasons fueling the expansion of the global bio-banking market is the rise in genomic research initiatives for the study of illnesses. The growing trend of preserving babies' cord blood stem cells for different health benefits, as well as public and private financing for regenerative medicine research, is driving the bio-banking market growth. The market is further influenced by the rise in the prevalence of major illnesses worldwide and the demand for cost-effective medication development. Additionally, the bio-banking market is favourably impacted by the growth of the biotechnology industry, improvements in the healthcare industry, population growth, an increase in healthcare spending, and breakthroughs in biobanking.

Biobanking for blood products

Blood products are expected to rise during the forecast period. This is explained by an increase in the occurrence of accidents and haematological illnesses. As the most frequently collected specimens and the primary sources of DNA and RNA, blood and blood products now account for the lion's share of the bio-banking market. The need for blood-related goods and the rising prevalence of blood-related illnesses are driving the expansion of blood products. Additionally, the growing elderly population is a major factor fueling the bio-banking market growth for blood products.

Virtual biobanks are gaining popularity

Data that has been collected and characterised from samples kept in conventional biobanks is made available in a virtual repository. The database of the virtual biobank provides high-resolution photographs of the samples and other identifying information. Virtual biobanks, which are frequently used in bioinformatics, include records for 2D and 3D microscopy on priceless clinical biopsy samples. This approach has become a viable choice for enhancing sample visibility and accessibility. Researchers may find the goods and services they require to manage and streamline key steps in the biobanking process by using virtual biobanks. Future growth of the bio-banking market is probably due to virtual system integration.

Rising adoption of regenerative drugs

Regenerative treatments aid in the induction of cell, tissue, and organ regeneration to assist them to regain their functionality. Every year, several requests for human clinical studies in regenerative medicine are submitted to the Food and Drug Administration (FDA). The rapid expansion of the global bio-banking market might be attributed to the regenerative medicine industry's ability to develop efficient treatments for chronic illnesses. The biobank has been a valuable resource for the development of regenerative therapies since it offers samples for study, development, and treatment. Investing in biobanking can result in significant cost recovery to support programmes for tissue engineering and regenerative medicine.

Europe is predicted to hold the largest market share for the biobanking market

Europe is anticipated to hold the largest share of the bio-banking industry. Well-established biobanks are present in European nations including Denmark, Norway, and Sweden, which has made a substantial contribution to the bio-banking market growth. Consequently, the biobanking sector has expanded as a result of the increasing sample supply in Europe. The bio-banking market expansion over the past few years has been aided by growing pharmaceutical company spending in R&D and greater usage of virtual biobanking technology in Europe.

Market Key Developments

  • In May 2023, The UK's Medicines and Healthcare Products Regulatory Agency (MHRA) established a genetic "biobank" to learn how a patient's genetic makeup may affect the safety of their medications.
  • In March 2023, Biodiversity Biobanks South Africa (BBSA) was established to manage and preserve biodiversity samples.
  • In June 2022, Mars Petcare revealed an unprecedented research project intended to advance knowledge of pet health and illness and support the development of individualised pet healthcare by scientists and veterinarians.

Segmentation:

By Sample Type

  • Blood Products
  • Human Tissues
  • Cell Lines
  • Nucleic Acids
  • Biological Fluids
  • Human Waste Products

By Ownership

  • Universities
  • National/Regional Agencies
  • Non-Profit Organizations
  • Private Organizations

By Application

  • Regenerative Medicine
  • Life Science Research
  • Clinical Research

By End-Use

  • Pharmaceutical Companies
  • Academic & Research Institutes
  • Hospitals

By Geography

  • North America
  • United States
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • United Kingdom
  • Germany
  • France
  • Spain
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Others
  • Asia Pacific
  • Japan
  • China
  • India
  • South Korea
  • Indonesia
  • Thailand
  • Others

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. Market Overview
  • 1.2. Market Definition
  • 1.3. Scope of the Study
  • 1.4. Market Segmentation
  • 1.5. Currency
  • 1.6. Assumptions
  • 1.7. Base, and Forecast Years Timeline

2. RESEARCH METHODOLOGY

  • 2.1. Research Data
  • 2.2. Assumptions

3. EXECUTIVE SUMMARY

  • 3.1. Research Highlights

4. MARKET DYNAMICS

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porter's Five Force Analysis
    • 4.3.1. Bargaining Power of Suppliers
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. Threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Industry
  • 4.4. Industry Value Chain Analysis

5. BIOBANKING MARKET, BY SAMPLE TYPE

  • 5.1. Introduction
  • 5.2. Blood Products
  • 5.3. Human Tissues
  • 5.4. Cell Lines
  • 5.5. Nucleic Acids
  • 5.6. Biological Fluids
  • 5.7. Human Waste Products

6. BIOBANKING MARKET, BY OWNERSHIP

  • 6.1. Introduction
  • 6.2. Universities
  • 6.3. National/Regional Agencies
  • 6.4. Non-Profit Organizations
  • 6.5. Private Organizations

7. BIOBANKING MARKET, BY APPLICATION

  • 7.1. Introduction
  • 7.2. Regenerative Medicine
  • 7.3. Life Science Research
  • 7.4. Clinical Research

8. BIOBANKING MARKET, BY END-USE

  • 8.1. Introduction
  • 8.2. Pharmaceutical Companies
  • 8.3. Academic & Research Institutes
  • 8.4. Hospitals

9. BIOBANKING MARKET, BY GEOGRAPHY

  • 9.1. Introduction
  • 9.2. North America
    • 9.2.1. United States
    • 9.2.2. Canada
    • 9.2.3. Mexico
  • 9.3. South America
    • 9.3.1. Brazil
    • 9.3.2. Argentina
    • 9.3.3. Others
  • 9.4. Europe
    • 9.4.1. United Kingdom
    • 9.4.2. Germany
    • 9.4.3. France
    • 9.4.4. Spain
    • 9.4.5. Others
  • 9.5. The Middle East and Africa
    • 9.5.1. Saudi Arabia
    • 9.5.2. UAE
    • 9.5.3. Israel
    • 9.5.4. Others
  • 9.6. Asia Pacific
    • 9.6.1. Japan
    • 9.6.2. China
    • 9.6.3. India
    • 9.6.4. South Korea
    • 9.6.5. Indonesia
    • 9.6.6. Thailand
    • 9.6.7. Others

10. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 10.1. Major Players and Strategy Analysis
  • 10.2. Market Share Analysis
  • 10.3. Mergers, Acquisitions, Agreements, and Collaborations

11. COMPANY PROFILES

  • 11.1. Sapien Biosciences
  • 11.2. Hamilton Company
  • 11.3. UK Biobank
  • 11.4. Apollo Hospitals
  • 11.5. Banka Bio
  • 11.6. Labvantage
  • 11.7. Amgen
  • 11.8. BioKryo
  • 11.9. Thermo Fisher Scientific
  • 11.10. Cureline